<DOC>
	<DOC>NCT02368717</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy and safety of 4-week double-blind treatment with PENTASA enema compared with placebo enema in Chinese patients with mild to moderate active left-sided ulcerative colitis, followed by a maximal 28-week open-label extension phase with PENTASA enema and/or PENTASA tablets.</brief_summary>
	<brief_title>An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Newly diagnosed or recurrent mild to moderate leftsided active ulcerative colitis Mayo score of at least 4 but not greater than 10 points and a score of ≥ 2 for colonoscopy Extent of colonic involvement and endoscopy subscore of Mayo score as confirmed by colonoscopy The patient is compliant with Patient Daily Diary by having adequately responded to the questions on ≥5 of the most recent full 7 days before the Randomization Visit Negative stool test at screening to rule out parasites and bacterial pathogens Patients receiving &gt; 2g/day of oral 5aminosalicylic acid (5ASA) products, or receiving topical rectal 5ASA &gt; 3g/week, within 7 days prior to screening Severe/fulminant ulcerative colitis or toxic dilatation of the colon Prior bowel resection surgery Patients allergic to 5ASA and derivative, any of the excipients, aspirin, or salicylates Patients with one or more of the diseases: bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis and Crohn's disease Patients who are unable to fill in the Patient Daily Diary or follow datacapturing procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>